Study drug for relapsed or refractory lymphoid cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old and weigh at least 40 kg
- Have a confirmed diagnosis of a listed lymphoid cancer (such as certain B-cell lymphomas, CLL/SLL, or certain leukemias)
- Your cancer must be “relapsed or refractory,” meaning it came back or did not respond, after specific prior treatments or because standard options are not available
- Be able to do daily activities at least “moderately okay” (performance status score ≥50)
- Have blood test and organ function levels within required ranges (neutrophils, platelets, hemoglobin, liver and kidney tests)
- Be able to breathe adequately (dyspnea less than Grade 2 and oxygen level ≥92% on room air)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
This phase 1 trial tests an investigational treatment called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to previous therapies. The goal is to see if the drug is safe and effective.
Hear when a new Lymphoid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.